Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab - PubMed
5 hours ago
- #Proteomics
- #Nemolizumab
- #Atopic dermatitis
- Nemolizumab is effective against pruritus and eczema in atopic dermatitis by inhibiting IL-31 signaling.
- Study investigated plasma protein changes in 25 Japanese patients after a single 60 mg dose of nemolizumab.
- Proteomic analysis showed upregulation of neutrophil degranulation and integrin signaling pathways.
- Downregulation of PTEN signaling was observed post-treatment.
- Nemolizumab reversed disease-associated alterations in key pathways, though individual protein changes were modest.
- TARC/CCL17 was identified as a protein associated with pruritus and eczema severity.
- The study provides insights into systemic immune response changes induced by nemolizumab.